Thursday, July 11, 2024

CATEGORY

Regeneron

Pharmaceuticals Innovation as Seven Companies Join EUCOPE to Drive Healthcare Advancements Across Europe

The European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) has announced the addition of seven new members to its network. This significant development was revealed at...

Chronic Obstructive Pulmonary Disease Treatment Dupixent Approval by European Commission Marks New Era

Regeneron Pharmaceuticals and Sanofi announced that the European Commission (EC) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic...

Geographic Atrophy Treatments Face Setbacks as EU Drug Regulator Rejects Apellis’ Syfovre Again

For the second time in six months, the European Medicines Agency's (EMA) European Committee for Medicinal Products for Human Use (CHMP) has rejected Apellis’...

New Hope for Lymphoma Treatment: Positive EMA Opinion for Odronextamab

Lymphoma treatment with odronextamab has received a positive opinion for conditional marketing authorization from the European Medicines Agency's (EMA) Committee for Medicinal Products for...

Eosinophilic Esophagitis Phase 3 Trial Shows Positive Results for Dupixent in Children

Eosinophilic esophagitis (EoE) was the focus of a Phase 3 trial for Dupixent® (dupilumab), with Regeneron Pharmaceuticals, Inc. and Sanofi announcing the publication of...

Multiple Myeloma Treatment Advances: Regeneron Unveils Linvoseltamab Phase 1/2 Trial Data

Regeneron Pharmaceuticals announced that the 14-month median follow-up data from the pivotal Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple...

Polyarticular Juvenile Idiopathic Arthritis: FDA Approves Regeneron and Sanofi’s Kevzara for Treatment

Polyarticular juvenile idiopathic arthritis (pJIA) treatment has advanced with the Food and Drug Administration's (FDA) approval of Kevzara (sarilumab), developed by Regeneron and Sanofi,...

Chronic Obstructive Pulmonary Disease Treatment: FDA Priority Review Update for Dupixent® (Dupilumab) in Patients with Type 2 Inflammation

Chronic Obstructive Pulmonary Disease (COPD) treatment has taken a significant step forward as Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that the U.S....

Chronic Obstructive Pulmonary Disease Treatment with Dupixent Faces Potential Delay; Regeneron Reports Stagnant Eylea Sales

Sanofi and Regeneron's eagerly awaited approval of Dupixent for treating chronic obstructive pulmonary disease (COPD) may face a delay, as revealed by Regeneron CEO...

Chronic Rhinosinusitis Treatment Dupixent Aims for FDA Approval as Maintenance for Adolescents

Regeneron and Sanofi have received Priority Review from the FDA for their supplemental Biologics License Application (sBLA) seeking approval of Dupixent (dupilumab) as an...

Latest news